Introduction
============

In 2018, liver cancer ranked 6th in terms of incidence (841,000 new cases) and 4th in terms of overall mortality, with a mortality rate of 782,000 worldwide. Based on the histological classification of primary liver cancer, it can be divided into hepatocellular carcinoma (HCC; 75--85%), intrahepatic cholangiocarcinoma (10--15%), and other rare types ([@b1-ol-0-0-10962]). Although numerous treatment approaches are available for HCC, including liver transplantation, surgery, radiofrequency ablation, radioembolization, trans-arterial chemo-embolization and targeted therapy ([@b2-ol-0-0-10962]), improving the long-term survival for patients with HCC remains a challenge. Therefore, more effective molecular targets are urgently required in HCC.

microRNAs (miRNAs/miRs) constitute a class of small noncoding RNAs, which regulate target gene expression mainly at the post-transcription level ([@b3-ol-0-0-10962]). Previous studies have reported that miRNAs are closely related to a number of cellular processes (CCs), including cell cycle regulation, inflammation, differentiation, migration and apoptosis, thereby performing functional roles in the occurrence and progression of various cancer types ([@b4-ol-0-0-10962]). A number of previous studies have shown that miRNAs can act as biomarkers and therapeutic agents to improve the diagnosis, and therapy, of cancer ([@b5-ol-0-0-10962]--[@b7-ol-0-0-10962]). Despite these previous findings, it is important to identify potential novel molecular targets.

Recently, miR-100-5p has been identified as a biomarker in multiple types of cancer. For instance, miR-100-5p has been shown to inhibit autophagy and induce apoptosis in colorectal cancer cells by targeting autophagy protein 5 ([@b8-ol-0-0-10962]). Additionally, miR-100-5p enhances the chemosensitivity of breast cancer by targeting HCLS1-associated protein X-1 ([@b9-ol-0-0-10962]). Moreover, miR-100-5p suppresses tumor migration and invasion by targeting IGF1R in patients with nasopharyngeal carcinoma ([@b10-ol-0-0-10962]). miR-100-5p could also inhibit the growth and metastasis of gastric cancer by targeting zinc finger and BTB domain containing protein 7A ([@b11-ol-0-0-10962]). To date, few targets of miR-100-5p, such as polo like kinase 1, mammalian target of rapamycin (mTOR), Ras-related protein Rac1 (RAC1), isoprenylcystein carboxyl methyltransferase (ICMT) and insulin like growth factor 1 receptor (IGF1R), have been identified in HCC, which may be associated with tumor progression, as well as poor prognosis, due to the downregulation of miR-100-5p expression in patients with HCC ([@b12-ol-0-0-10962]--[@b15-ol-0-0-10962]). However, the previous studies were limited by small sample sizes and only several target genes of miR-100-5p have been identified in HCC. The clinical value of miR-100-5p in HCC and its molecular mechanisms are not fully understood.

In the present study, to further explore the clinical significance of miR-100-5p in HCC, the differential expression of miR-100-5p between HCC tissues and non-cancerous tissues was examined using meta-analysis based on the big data from The Cancer Genome Atlas (TCGA), The Gene Expression Omnibus (GEO) database and relevant literature ([Fig. 1](#f1-ol-0-0-10962){ref-type="fig"}). The present study also attempted to reveal the clinicopathological role and prognostic value of miR-100-5p using TCGA. Bioinformatics analysis was carried out to investigate the underlying mechanism of miR-100-5p in HCC, which may provide novel therapeutic targets for HCC.

Materials and methods
=====================

### Meta-analysis based on TCGA, GEO and relevant literature

Datasets about HCC were downloaded from the TCGA database ([@b16-ol-0-0-10962]) and were used to determine the expression level of miR-100-5p. Subsequently, the expression value of miR-100-5p was selected and converted using a log~2~ transformation. The GEO database ([ncbi.nlm.nih.gov/gds/](ncbi.nlm.nih.gov/gds/)) was used to screen for HCC datasets with the keywords '(hepatocellular OR liver OR hepatoma OR hepatic) AND (carcinoma OR cancer\* OR adenocarcinoma OR tumor OR malignan\* OR neoplas\*) AND (MicroRNA OR miRNA OR 'Micro RNA' OR mir OR 'Small Temporal RNA' OR 'non-coding RNA' OR ncRNA OR 'small RNA')' until 7th January 2019. The inclusion criteria were as follow: i) A least 3 HCC and noncancerous tissue samples, including paracarcinoma tissue and normal liver tissue in the microarray; ii) the expression of miR-100-5p was determined and calculated; and iii) profiling obtained from *Homo sapiens*. miRNA-sequencing (seq) data were excluded according to the following criteria: i) The miRNA-seq did not meet the inclusion criteria; ii) the miRNA-seq did not include the expression of miR-100-5p; iii) the miRNA-seq only provided HCC tissues without noncancerous tissues; and iv) microarrays used cell line samples. For additional information about miR-100-5p in HCC, PubMed and ArrayExpress were searched until 7th January 2019 using the following search strategy: (Carcinoma OR cancer OR tumour OR tumor OR adenocarcinoma OR neoplas\* OR malignan\*) AND (HCC OR hepatocellular OR hepatic OR liver) AND (microRNA-100 OR miR-100 OR miRNA-100 OR miR100 OR miRNA100 OR microRNA100 OR 'miR 100' OR 'miRNA 100' OR 'microRNA 100' OR miR-100-5p OR miRNA-100-5p OR microRNA-100-5p). The inclusion criteria were as aforementioned. The number of samples, mean and standard deviation between groups were obtained for a comprehensive meta-analysis. Fixed effects, random effects models, heterogeneity and sensitivity analysis were applied in the meta-analysis using Stata SE12.0 software (Stata Corp LLC). Publication bias was determined using Egger\'s plot and Begg\'s funnel ([@b17-ol-0-0-10962]).

### Exploring the clinical value of miR-100-5p and its hub genes

The differential expression of miR-100-5p was computed between HCC tissues and noncancerous tissues using Student\'s unpaired t-test. The association between miR-100-5p levels and clinicopathological features were then evaluated based on the TCGA dataset using a Student\'s unpaired t-test. Patients with HCC were divided into high and low expression groups according to the median expression level. The prognostic value of miR-100-5p and its hub genes in HCC patients (survival time \>90 days) was estimated using Kaplan-Meier analysis and log rank tests. Analysis was carried out using GraphPad Prism 7.04 (GraphPad Software, Inc.). P\<0.05 was considered to indicate a significant difference.

### Predicting target genes of miR-100-5p

miRWalk 2.0 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>) provides an intuitive interface for generating predicted and validated miRNA-binding sites for known genes in humans, mouse, rat, dog and cow ([@b18-ol-0-0-10962]), and was used to predict the target gees of miR-100-5p. The prospective target genes of miR-100-5p were obtained from 12 different databases (miRWalk2.0, miRanda-rel2010 ([@b19-ol-0-0-10962]), DIANA-microTv5.0 ([@b20-ol-0-0-10962]), miRNAMap2.0 ([@b21-ol-0-0-10962]), miRBridge4.0 ([@b22-ol-0-0-10962]), miRMap4.0 ([@b23-ol-0-0-10962]), PicTar2 ([@b24-ol-0-0-10962]), PITA2007 ([@b25-ol-0-0-10962]), miRDB4.0 ([@b26-ol-0-0-10962]), RNAhybrid2.1 ([@b27-ol-0-0-10962]), RNA22v2 ([@b28-ol-0-0-10962]) and TargetScan6.1 ([@b29-ol-0-0-10962]). The target genes of miR-100-5p that appeared in ≥4 different databases were selected for further analysis.

### GO and KEGG clustering analysis

DAVID 6.7 (<https://david-d.ncifcrf.gov/>), an online open platform that disseminates biologically abundant information across a comprehensive analysis of large gene lists, was used for clustering analysis ([@b30-ol-0-0-10962]). Potential target genes were searched in the annotated portal DAVID. Based on the DAVID database, enrichment annotation was performed, using GO ([geneontology.org/](geneontology.org/)) and KEGG ([genome.jp/kegg/](genome.jp/kegg/)). Statistically significant GO and KEGG terms (P\<0.05) were selected.

### Construction of a protein-protein interaction (PPI) network

Cytoscape 3.7 ([@b31-ol-0-0-10962]) was used to visualize the interaction networks of hub gene products in HCC. A PPI network was constructed using the StringApp plugin, which enabled Cytoscape 3.7 to link to the STRING database (<https://string-db.org/>). Thereafter, the gene symbols with a degree \>7 were selected from the PPI network, with the aim of identifying the most likely hub genes of miR-100-5p in patients with HCC.

### Correlation analysis

Gene expression data (log~2~ transformation) in HCC were downloaded from the TCGA database. In order to reveal the association between miR-100-5p and its candidate genes, Spearman\'s correlation analysis was performed, and linear regression plots were constructed using GraphPad Prism 7.04.

### Detection of the expression of hub genes

The differential expression of the hub genes was evaluated in patients with HCC based on the Roessler\'s (GSE14520) ([@b32-ol-0-0-10962]) and Chen\'s dataset (GSE3500) ([@b33-ol-0-0-10962]) from the GEO database. Differences in the expression of the hub genes were visualized using boxplots. In addition, the protein expression of hub genes was verified using The Human Protein Atlas ([proteinatlas.org](proteinatlas.org)), which provides a large number of antibody-based images ([@b34-ol-0-0-10962]).

### Detecting alterations in hub genes

The cBio Cancer Genomics Portal (<http://cbioportal.org>), a public resource that provides a convenient interface for accessing the multidimensional cancer genomics and clinical data based on multiple platforms ([@b35-ol-0-0-10962]), was used to detect alterations in hub genes and to investigate the association between alterations and outcomes for patient.

### Determining alternative splicing of hub genes

TCGA SpliceSeq (<http://bioinformatics.mdanderson.org/TCGASpliceSeq>) is a database that enables investigators to explore the alternative splicing events of various tumors based on TCGA data ([@b36-ol-0-0-10962]). In general, seven alternative splicing events were classified, including alternate donor (AD) sites, alternate terminators (ATs), alternate promoters (APs), alternate acceptor (AA) sites, exon skipping (ES), retained introns (RIs) and mutually exclusive exons (MEs) ([@b37-ol-0-0-10962]). Accordingly, the splicing events of the hub genes in HCC were extracted from TCGA SpliceSeq. Percent spliced in (PSI) values, an intuitive ratio for quantifying splicing events ([@b38-ol-0-0-10962]), were then compared between HCC and the normal tissues with Student\'s unpaired t-test using GraphPad Prism 7.04.

Results
=======

### Differences in the expression of miR-100-5p between groups

The scatter plot presented in [Fig. 2](#f2-ol-0-0-10962){ref-type="fig"} demonstrates that miR-100-5p expression was significantly reduced in the HCC group compared with the non-cancerous group based on TCGA data (P\<0.0001). In total, there were 16 microarray datasets, one TCGA study and one published article ([Table I](#tI-ol-0-0-10962){ref-type="table"}), these included a total of 1,258 samples (806 HCC and 452 non-cancerous tissues) for the comprehensive meta-analysis ([Fig. 3](#f3-ol-0-0-10962){ref-type="fig"}). The fixed effects model indicated that the pooled standard mean difference (SMD) was −0.90 (95% CI, −1.04 to −0.77; I^2^, 66.0%; P\<0.001), while the pooled SMD was −1.00 (95% CI, −1.28 to −0.72; I^2^, 66.0%; P\<0.001) in the random effects model. Influence analysis revealed that two microarrays (GSE22058 and GSE21362), the TCGA data and one article may lead to heterogeneity. After removing the two microarrays (GSE22058 and GSE21362), the TCGA data and the article, the pooled SMD was −0.94 (95% CI, −1.14 to −0.74; I^2^, 35.2%; P=0.093). It was determined that there was no publication bias by performing Begg\'s test (P=0.705) and Egger\'s test (P=0.443; [Fig. 4](#f4-ol-0-0-10962){ref-type="fig"}). The meta-analysis indicated that the expression of miR-100-5p was significantly decreased in HCC tissue compared with non-cancerous tissue.

### Clinical value of miR-100-5p in HCC with TCGA data

The association between the expression of miR-100-5p and the clinicopathological features of patients with HCC was investigated. The clinicopathological parameters of the patients with HCC are presented in [Table II](#tII-ol-0-0-10962){ref-type="table"}. Significance was determined for the following clinicopathological parameters: Age (P=0.049), tumor stage (P=0.022), tumor node metastasis (TNM) stage (P=0.020), tumor grade (P\<0.001), non-alcoholic fatty liver disease (NAFLD; P\<0.001) and α-fetoprotein (AFP) level (P\<0.001). However, there was no statistical significance in liver cirrhosis, sex, lymph node stage, metastasis stage, Child-Pugh classification grade, hepatitis B virus or hepatitis C virus infection and alcohol consumption. Furthermore, survival analysis suggested that patients with HCC and lower expression levels of miR-100-5p exhibited significantly less favorable OS times (P=0.0003) compared with patients with higher expression levels of miR-100-5p ([Fig. 5](#f5-ol-0-0-10962){ref-type="fig"}). The median survival of patients with high and low miR-100-5p expression were 2456 and 1372 days, respectively, indicating that miR-100-5p overexpression is associated with a better clinical outcome for patients with HCC.

### Potential target genes of miR-100-5p

The target genes of miR-100-5p were identified using the following 12 target gene prediction platforms: miRWalk, miRanda, miRNAMap, Microt4, miRBridge, PicTar, PITA, miRMap, miRDB, RNAhybrid, RNA22 and TargetScan. In total, 447 candidate hub genes ([Table SI](#SD1-ol-0-0-10962){ref-type="supplementary-material"}) for miR-100-5p were predicted by at least 4 of the 12 online platforms used in the present study.

### GO annotation and KEGG pathway

GO and KEGG annotation of the 447 potential hub genes of miR-100-5p was conducted using the online platform DAVID. GO annotation revealed that a total of 99 terms were significantly enriched (P\<0.05) through the candidate genes identified. KEGG analysis identified four signaling pathways that were significantly enriched. The top 10 enriched GO terms and the significant KEGG pathways, which may contribute to targeted therapy for patients with HCC, are presented in [Fig. 6](#f6-ol-0-0-10962){ref-type="fig"}. GO annotation showed that the three most significant terms for biological processes (BPs) were 'regulation of transcription', 'transcription', and 'negative regulation of transcription, DNA-dependent' ([Fig. 6B](#f6-ol-0-0-10962){ref-type="fig"}). For cellular components (CCs), the candidate genes most significantly enriched were 'chromatin remodeling complex', 'membrane fraction' and 'plasma membrane part' ([Fig. 6C](#f6-ol-0-0-10962){ref-type="fig"}). In molecular functions (MFs), 'transcription regulator activity', 'DNA binding' and 'ion binding' were the terms most commonly associated with the target genes ([Fig. 6D](#f6-ol-0-0-10962){ref-type="fig"}). The two most significant KEGG pathways identified were involved in cancer and heparan sulfate biosynthesis ([Fig. 6A](#f6-ol-0-0-10962){ref-type="fig"}).

### PPI network analysis

A PPI network was constructed, consisting of 158 nodes and 229 lines, by inputting a total of 447 potential target genes into String App ([Fig. 7](#f7-ol-0-0-10962){ref-type="fig"}). Each protein may interact with multiple proteins, which may form the underlying molecular regulatory mechanism of miR-100-5p in HCC. In total, the following 6 hub genes were identified based on a degree \>7 in the PPI network: Histone deacetylase (HDAC)2, HDAC3, SHC transforming protein 1 (SHC1), RAC1, IGF1R and E3-unbiqitin protein ligase CBL (CBL). The six key genes may exert an important function in the regulatory mechanism of miR-100-5p in HCC.

### Spearman correlation analysis

Spearman correlation analysis revealed that HDAC2 (r= −0.3878; P\<0.0001), HDAC3 (r= −0.1816; P=0.0005), SHC1 (r= −0.2894; P\<0.0001), RAC1 (r= −0.386; P\<0.0001) and CBL (r= −0.1259; P=0.0158) were inversely associated with miR-100-5p expression. IGF1R (r= −0.0876; P=0.0936) exhibited a trend towards negative correlation with miR-100-5p expression, although this was not statistically significant ([Fig. 8](#f8-ol-0-0-10962){ref-type="fig"}).

### Protein levels of hub genes

The protein levels of HDAC2 (antibody, CAB005054), HDAC3 (antibody, CAB005583), SHC1 (antibody, CAB016305), RAC1 (antibody, CAB035994), IGF1R (antibody, CAB010268) and CBL (antibody, HPA027956) in HCC and noncancerous tissue were obtained from the Human Protein Atlas database. As presented in [Fig. 9](#f9-ol-0-0-10962){ref-type="fig"}, HDAC2, HDAC3, SHC1 and IGF1R exhibited high staining and strong intensity in HCC. RAC1 and CBL exhibited medium staining and an average intensity in HCC. However, in normal liver tissue, IGF1R and SHC1 exhibited moderate and low staining, respectively. The protein expression levels of HDAC2, HDAC3, RAC1 and CBL were below the limit of detection in normal liver tissue.

### Expression and prognostic significance of hub genes

Of the 6 hub genes, 4 genes (HDAC2, HDAC3, SHC1 and RAC1) exhibited overexpression according to Roessler\'s dataset and Chen\'s dataset from the GEO database. As shown in [Fig. 10A and B](#f10-ol-0-0-10962){ref-type="fig"}, the expression levels of HDAC2 in both Roessler\'s dataset \[P=4.21×10^−46^; fold change (FC), 1.806\] and Chen\'s dataset (P=0.007; FC, 1.191) were significantly upregulated in HCC tissue compared with the normal liver tissue. The expression of HDAC3 in Chen\'s dataset was significantly higher in HCC tissues compared with the normal liver tissue ([Fig. 10C](#f10-ol-0-0-10962){ref-type="fig"}; P=1.24×10^−6^; FC, 1.314). The expression of RAC1 (P=7.91×10^−46^; FC, 1.422) and SHC1 (P=4.91×10^−25^; FC, 1.613) in Roessler\'s dataset were significantly increased in HCC tissues compared with the normal liver tissue ([Fig. 10D and E](#f10-ol-0-0-10962){ref-type="fig"}). As miR-100-5p is downregulated in HCC, the genes with increased expression in HCC are potential target genes of miR-100-5p. As presented in [Fig. 11](#f11-ol-0-0-10962){ref-type="fig"}, it was found that higher expression levels of HDAC2 (HR, 1.910; 95% CI, 1.309--2.787; P=0.0007), HDAC3 (HR, 1.474; 95% CI, 1.012--2.146; P=0.0435), SHC1 (HR, 1.52; 95% CI, 1.043--2.215; P=0.0281) and RAC1 (HR, 1.817; 95% CI, 1.248--2.645; P=0.0022) were significantly associated with worse OS.

### Alterations of hub genes

Gene alteration analysis of the 6 hub genes in the 360 TCGA patients were analyzed using the cBioPortal database, this analysis indicated that the main types of gene alteration were mRNA upregulation and amplification. In total 7, 11, 21, 12, 11 and 6% of cases had genetic alterations in HDAC2, HDAC3, SHC1, RAC1, IGF1R and CBL, respectively ([Fig. S1](#SD1-ol-0-0-10962){ref-type="supplementary-material"}). The alterations in HDAC2 (log rank P=0.0213), SHC1 (log rank P=6.153×10^−3^) and RAC1 (log rank P=0.0144) were associated with a poorer OS in patients with HCC from the TCGA dataset, while the alterations that occurred in HDAC3, IGF1R and CBL were not significantly associated with OS ([Fig. S2](#SD1-ol-0-0-10962){ref-type="supplementary-material"}). The changes in HDAC2 (log rank P=6.488×10^−3^), SHC1 (log rank P=0.0347) and IGF1R (log rank P=6.991×10^−3^) were associated with unfavorable disease-free survival (DFS) in patients with HCC from the TCGA dataset, whereas alterations in HDAC3, RAC1 and CBL were not significantly associated with DFS ([Fig. S3](#SD1-ol-0-0-10962){ref-type="supplementary-material"}).

### Alternative splicing of hub genes

In total, the splicing events of 4 genes (HDAC2, HDAC3, SHC1 and RAC1) were analyzed. To define a splicing event accurately, each splicing event was named with a unique code in the present study. For example, for the code SHC1-7856-AA, SHC1 is the gene symbol, 7856 denotes the order number of the splicing event in the dataset and AA indicates the type of splicing. The results showed that alternative splicing event SHC1-7856-AA was significantly decreased in HCC (P\<0.0001), while RAC1-78720-ES was significantly increased (P=0.0253; [Fig. S4](#SD1-ol-0-0-10962){ref-type="supplementary-material"}). However, no statistically significant alternative splicing events were identified in HDAC2 and HDAC3 (P\>0.05). These findings may facilitate the understanding of the potential molecular mechanisms of the target genes.

Discussion
==========

HCC is the most common type of primary liver cancer ([@b1-ol-0-0-10962]); however, predicting the outcome for patients remains a challenge. Identifying prospective biomarkers and understanding the underlying mechanisms of HCC may provide novel therapeutic, prognostic and monitoring strategies for HCC. The present study aimed to identify hub genes and signaling pathways regulated by miR-100-5p, and to elucidate the role of this miRNA in HCC. It has been reported that miR-100-5p functions in diverse human cancers. For example, previous studies reported that miR-100-5p could reverse cisplatin resistance in breast cancer, lung cancer and ovarian cancer ([@b9-ol-0-0-10962],[@b39-ol-0-0-10962]--[@b41-ol-0-0-10962]). Previous studies have also reported that miR-100 may influence the metastatic potential of various cancers, including prostate cancer, gastric cancer and nasopharyngeal carcinoma ([@b10-ol-0-0-10962],[@b11-ol-0-0-10962],[@b42-ol-0-0-10962],[@b43-ol-0-0-10962]). It has been proposed that high levels of miR-100-5p are associated with a longer survival time in patients with various types of cancer, including glioblastoma and epithelial ovarian cancer ([@b44-ol-0-0-10962],[@b45-ol-0-0-10962]). In two studies by Zhou *et al* ([@b13-ol-0-0-10962],[@b14-ol-0-0-10962]), miR-100-5p was found to target mTOR and block the mTOR-p70S6K signaling pathway in order to downregulate the protein level of angiopoietin 2, thus abrogating the vessels that encapsulated tumor cluster-dependent metastasis of hepatoma cells. The decreased expression of miR-100-5p can enhance ICMT-RAC1 signaling and promote the metastasis of HCC cells ([@b13-ol-0-0-10962],[@b14-ol-0-0-10962]). Furthermore, Ge *et al* ([@b15-ol-0-0-10962]) reported that miR-100-5p may reduce mTOR and IGF-1R levels by promoting the autophagy of hepatocellular carcinoma cells. A study by Petrelli *et al* ([@b46-ol-0-0-10962]) revealed that dysregulation of miR-100-5p was likely to be an early event in the development of hepatocarcinogenesis. However, the biological functions and mechanisms of miR-100-5p expression in HCC are still not completely understood.

To the best of our knowledge, only 3 studies ([@b12-ol-0-0-10962],[@b13-ol-0-0-10962],[@b46-ol-0-0-10962]) have reported that the expression of miR-100-5p is decreased in HCC, with 2 of these 3 studies ([@b12-ol-0-0-10962],[@b13-ol-0-0-10962]) indicating that low expression of miR-100-5p is associated with clinicopathological features in patients with HCC. However, Varnholt *et al* ([@b47-ol-0-0-10962]) reported that the level of miR-100-5p was significantly increased in HCC tissues compared with normal tissues. Similarly, the upregulation of miR-100-5p in plasma or serum samples was demonstrated by Wang *et al* ([@b48-ol-0-0-10962]). As aforementioned, the expression of miR-100-5p in patents with HCC remains controversial. Therefore, the present study conducted a meta-analysis to understand whether miR-100-5p expression is decreased in HCC samples compared with its expression in non-HCC samples. In the present study, it was found that miR-100-5p was downregulated in HCC based on a total of 1,258 samples from TCGA, GEO and relevant articles. Reduced expression of miR-100-5p was associated with poorer OS and worse clinical parameters compared with normal miR-100-5p expression. Although the nature of the present study was similar to a study conducted by Chen *et al* ([@b12-ol-0-0-10962]), the findings of the present study were novel and provided further information as follows: i) The present study detected differences in the expression of miR-100-5p with a larger sample size (1,258 samples) based on the meta-analysis; ii) the present study suggested that miR-100-5p may be used to predict the progression of HCC due to the close associated between miR-100-5p expression and clinicopathological features, including age, tumor stage, TNM stage, tumor grade, NAFL and AFP level; and iii) the results of the current study suggested that miR-100-5p may serve as a reliable biomarker, with higher expression of miR-100-5p indicating a better OS. Further investigations focusing on the association between miR-100-5p and HCC are required. In the present study bioinformatics analysis was performed to identify the potential molecular mechanisms of miR-100-5p in HCC. For BPs, the top five related GO terms were 'regulation of transcription', 'transcription', 'negative regulation of transcription', 'regulation of receptor-mediated endocytosis' and 'DNA-dependent, negative regulation of RNA metabolic process'. For CCs, the top five statistically significant terms were 'chromatin remodeling complex', 'membrane fraction', 'plasma membrane part', 'insoluble fraction' and 'nucleoplasm'. For MFs, the top 5 terms were 'transcription regulator activity', 'transcription factor activity', 'DNA binding', 'ion binding' and 'metal ion binding'. These results suggest the target genes primarily functioned in transcriptional regulation by binding to chromatin, DNA or other biological molecules, thus affecting the occurrence and development of HCC. For the KEGG pathway analysis, the two most statistically significant pathways were 'pathways in cancer' and 'heparan sulfate biosynthesis'. Heparan sulfate is a linear polysaccharide that modulates numerous biological processes, including cell growth, angiogenesis and adhesion ([@b49-ol-0-0-10962]--[@b51-ol-0-0-10962]). A study by Cassinelli *et al* ([@b52-ol-0-0-10962]) found that the heparanase/heparan sulfate proteoglycan axis may be a potential novel therapeutic target in sarcomas. Ling *et al* ([@b53-ol-0-0-10962]) suggested that blocking heparan sulfate function in the heparin-binding domains of fibroblast growth factor receptor 1 inhibited growth of cancer cells. Dudás *et al* ([@b54-ol-0-0-10962]) showed that heparin and heparan sulfate may interfere with the function of topotecan in liver and liver cancer. Given these previous findings, it was hypothesized that miR-100-5p may exert a regulatory function on the biosynthesis of heparan sulfate, which may provide potential candidate targets for drug development in HCC. However, this should be verified in the future with experimental studies.

Additionally, 6 possible candidate genes, HDAC2, HDAC3, SHC1, RAC1, IGF1R and CBL, were identified by constructing a PPI network and were selected as they had a degree \>7. The expression of HDAC2, HDAC3, SHC1 and RAC1 were significantly increased in HCC tissue compared with non-cancerous tissue. Survival analysis showed that the upregulation of HDAC2, HDAC3, SHC1 and RAC1 were associated with poorer outcome for patients with HCC.

The proteins encoded for by HDAC2 and HDAC3 belonged to the histone deacetylase family ([@b55-ol-0-0-10962],[@b56-ol-0-0-10962]). Previous studies have reported that these genes are involved in various BPs, such as cell cycle progression and transcriptional regulation ([@b57-ol-0-0-10962]--[@b59-ol-0-0-10962]). HDAC2 and HDAC3 have been found to be closely associated with the occurrence and survival rate in various cancer types, including colon cancer, breast cancer and HCC ([@b60-ol-0-0-10962]--[@b64-ol-0-0-10962]). The aforementioned studies also support the findings of the present study in which high expression of HDAC2 and HDAC3 was found to indicate a poorer prognosis for patients with HCC. To the best of our knowledge, the association between miR-100-5p and the two genes, HDAC2 and HDAC3, has not previously been identified. In the present study it was reported that miR-100-5p is closely linked with HDAC2 and HDAC3, however, experiments should be performed to support these findings.

The gene encoding SHC1 encodes three main isoforms, including p66Shc, p52Shc and p46Shc. The p66Shc isoform may participate in modulating lifetime and the effects of reactive oxygen species ([@b65-ol-0-0-10962]). The other two isoforms, p52Shc and p46Shc, may be involved in the transforming activity of oncogenic tyrosine kinases ([@b66-ol-0-0-10962],[@b67-ol-0-0-10962]). Recently, various studies have found that this gene is closely related to a variety of cancer types. In one previous study, Zhang *et al* ([@b68-ol-0-0-10962]) found that p66Shc was highly expressed in colon cancer tissue, and knockdown of p66Shc in HCT8 cells reduced proliferation and accelerated apoptosis. A study by Yukimasa *et al* ([@b69-ol-0-0-10962]) also suggested that increased expression of p46Shc and p52Shc may be related to the occurrence of gastric cancer. In addition, Muniyan *et al* ([@b70-ol-0-0-10962]) reported that p66Shc was highly expressed in ovarian cancer cells compared with noncancerous cells, and that it may regulate the proliferation of human ovarian cancer cells. Furthermore, a previous study also identified that elevated expression of p66Shc was associated with the advance and metastasis of prostate cancer ([@b71-ol-0-0-10962]). At present, to the best of our knowledge, studies focusing on the regulatory mechanism of SHC1 in HCC are scarce. Yoshida *et al* ([@b72-ol-0-0-10962]) reported that the upregulation of SHC1 was closely associated with shorter survival in patients with HCC patients. In the present study, it was found that the expression of SHC1 was significantly increased in HCC tissue compared with non-cancerous tissue, and was closely associated with the outcome of patients with HCC. In the enriched GO terms, SHC1 was found to be strongly associated with 'regulation of cell proliferation', 'positive regulation of cellular biosynthetic process' and 'positive regulation of macromolecule biosynthetic process'. Therefore, it was hypothesized that miR-100-5p may target SHC1 to regulate cell proliferation and biosynthetic processes, thus contributing to the progression of HCC. However it is necessary to conduct experiments *in vivo* and *in vitro* to validate this hypothesis.

RAC1 is important for a variety of cellular functions, including proliferation, adhesion, motility, migration and metastasis of tumor cells ([@b73-ol-0-0-10962]). Recently, Cheng *et al* ([@b74-ol-0-0-10962]) reported that RAC1 was upregulated in hypopharyngeal squamous cell carcinoma (HSCC) tissues, and that the silencing of RAC1 could reduce the invasion and migration abilities of HSCC cells. Consistently, the upregulation of RAC1 has been reported to be associated with poorer outcomes for patients with breast cancer ([@b75-ol-0-0-10962]). RAC1 inhibition may prevent metastasis and augment chemotherapy in gastric adenocarcinoma cells by blocking epithelial to mesenchymal transition (EMT) and cancer stem cell phenotypes ([@b76-ol-0-0-10962]). A previous study found that downregulation of miR-100-5p enhanced ICMT/RAC1 signaling and promoted the progression of HCC cells ([@b13-ol-0-0-10962]). In the present study, it was found that the expression of RAC1 was significantly higher in HCC tissue compared with normal tissue, and was inversely related to the expression of miR-100-5p. According to bioinformatics analysis, RAC1 was enriched in various BPs, such as 'regulation of receptor-mediated endocytosis', 'cell morphogenesis', 'cellular component morphogenesis' and 'epithelial cell differentiation'. These BPs play important roles in the growth, migration and differentiation of tumor cells, thereby contributing to the occurrence and development of cancer ([@b77-ol-0-0-10962]--[@b80-ol-0-0-10962]). Additionally, the data in the present study revealed that the upregulation of RAC1 was associated with poorer OS in patients with HCC. Therefore, it was hypothesized that the miR-100-5p/RAC1 signaling pathway may be important in the metastasis of HCC, and hence, may influence prognosis of patients with HCC. This indicates that interfering with the miR-100-5p/RAC1 signaling pathway may provide a novel treatment strategy for HCC. Nevertheless, further studies are required to support this hypothesis.

A number of previous studies have suggested that genetic alterations may affect the occurrence and progression of tumor ([@b81-ol-0-0-10962]--[@b83-ol-0-0-10962]). Jonckheere *et al* ([@b84-ol-0-0-10962]) reported that K-RAS mutation was the earliest genetic alteration occurring in pancreatic ductal adenocarcinoma, which could alter the expression of miRNA. In the present study, alterations in 6 key hub genes (HDAC2, HDAC3, SHC1, RAC1, IGF1R and CBL) were identified. The main alterations identified in the hub genes were amplification and mRNA upregulation. Alterations in HDAC2, SHC1, RAC1 and IGF1R were closely associated with a poorer outcome for patients with HCC. It is anticipated that these genetic alterations may be associated with the downregulation of miR-100-5p, thus playing an important role in the progression of HCC. However, further studies are required.

Alternative splicing is a common mechanism for gene regulation in humans, and it plays an important role in tumorigenesis, progression and therapy ([@b85-ol-0-0-10962],[@b86-ol-0-0-10962]). Generally, miRNAs work by binding to the 3′untranslated regions (UTRs) of their target genes ([@b87-ol-0-0-10962]). However, other functions of miRNAs are being identified. For example, Teplyuk *et al* ([@b88-ol-0-0-10962]) revealed that miR-10b can modulate the splicing events of its target genes by binding to 5′UTRs in intracranial glioblastoma ([@b88-ol-0-0-10962]). In the present study, it was found that the splicing events SHC1-7856-AA and RAC1-78720-ES were significantly decreased and increased in HCC compared with normal tissue, respectively, which may indicate that miR-100-5p is associated with alternative splicing of SHC1 and RAC1. Overall, the mechanism of how miR-100-5p influences its target genes warrants further study.

Although the results of the present study suggest that miR-100-5p may function as a tumor suppressor and be a valuable prognostic biomarker for HCC, it should be emphasized that several limitations exist in the present study. As only one previous study ([@b48-ol-0-0-10962]) involving serum samples could be found, no meta-analysis on circulating miRNAs could be performed. The current study therefore was unable to provide a minimally invasive method and early prognostic indicator for patients with HCC. The sample population for the clinical parameters was small, despite being larger than previous studies, which was likely to limit the stability of results. In order to comprehensively explore the potential value of miR-100-5p, this study was extended to investigate numerous non-cancerous samples ([@b16-ol-0-0-10962]). However, a subgroup analysis is needed to reveal more accurate conclusions in future studies. In addition, even though predictions were performed on an array of candidate genes, only two genes (RAC1 and IGF1R) have been experimentally verified ([@b13-ol-0-0-10962],[@b15-ol-0-0-10962]). More candidate genes must be verified with *in vivo* and *in vitro* experiments. The nature of the present study was itself a limitation and a prospective cohort study is expected to be conducted to verify the functions of miR-100-5p in HCC.

In conclusion, miR-100-5p was significantly downregulated in HCC based on the meta-analysis performed in the present study. The downregulation of miR-100-5p was found to be closely associated with a poorer prognosis and poorer clinical characteristics, including NAFLD, in patients with HCC, which indicated that miR-100-5p may function in the development and progression of HCC through multiple biological mechanisms. The overexpression of the 4 potential target genes (HDAC2, HDAC3, SHC1 and RAC1) of miR-100-5p were associated with poorer survival for patients with HCC. Therefore, miR-100-5p and these potential target genes may provide novel therapeutic strategies and biomarkers for the diagnosis and prognosis of patients with HCC.
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![Expression of miR-100-5p was significantly decreased in the HCC group (372 samples) compared with the non-cancerous group (50 samples) from TCGA. miR, microRNA; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.](ol-18-06-6126-g01){#f2-ol-0-0-10962}

###### 

Meta-analysis of the differential expression of miR-100-5p in HCC and non-cancerous tissues. (A) Forest plot of miR-100-5p expression datasets from Gene Expression Omnibus, TCGA and an article. The fixed effects model indicated that the pooled SMD was −0.90 (95% CI, −1.04 to −0.77; I^2^, 66.0%; P\<0.001. (B) Forest plot of the pooled SMD of miR-100-5p was −1.00 (95% CI, −1.28 to −0.72; I^2^, 66.0%; P\<0.001) using the random effects model. Meta-analysis of the differential expression of miR-100-5p in HCC and non-cancerous tissues. (C) Sensitivity analysis of the included studies. (D) Forest plot with the data leading to heterogeneity removed. The pooled SMD was −0.94 (95% CI, −1.14 to −0.74; I^2^, 35.2; P=0.093). miR, microRNA; HCC, hepatocellular carcinoma; CGA, The Cancer Genome Atlas; SMD, standard mean difference; CI, confidence interval.
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![Determination of publication bias. No significant publication bias was found using (A) Begg\'s test (P=0.705) or (B) Egger\'s test (P=0.443). s.e., standard error; SMD, standard mean difference.](ol-18-06-6126-g04){#f4-ol-0-0-10962}

![Prognosis value of miR-100-5p. The association between miR-100-5p expression and overall survival of patients with hepatocellular carcinoma based on The Cancer Genome Atlas cohort (P=0.0003). miR, microRNA.](ol-18-06-6126-g05){#f5-ol-0-0-10962}

###### 

GO and KEGG analysis of microRNA-100-5p. (A) In total, 4 significant KEGG pathways were identified. The top 10 significant GO terms in (B) biological processes. GO and KEGG analysis of microRNA-100-5p. (A) In total, 4 significant KEGG pathways were identified. The top 10 significant GO terms in (C) cellular components and (D) molecular functions. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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![Protein-protein interaction network for the potential target genes of microRNA-100-5p. Each node denotes a gene product and lines represent the associations between gene products.](ol-18-06-6126-g08){#f7-ol-0-0-10962}

![Spearman correlation analysis between miR-100-5p and potential target genes. (A) HDAC2 (r= −0.387; P\<0.0001); (B) HDAC3 (r= −0.1816; P=0.0005); (C) SHC1 (r= −0.2894; P\<0.0001); (D) RAC1 (r= −0.386; P\<0.0001); (E) IGF1R (r= −0.0876; P=0.0936); and (F) CBL (r= −0.1259; P=0.0158). miR, microRNA; HDAC, histone deacetylate; SHC1, SHC-transforming protein 1; RAC1, Ras-related protein Rac1; IGF1R, insulin like growth factor 1 receptor; CBL, E3 ubiquitin-protein ligase CBL.](ol-18-06-6126-g09){#f8-ol-0-0-10962}

![Immunohistochemical staining (magnification, ×40 or ×400) for protein expression of the 6 hub genes of miR-100-5p. (A) High staining and strong intensity of HDAC2 in HCC (antibody, CAB005054). (B) Low expression of HDAC2 in normal liver tissue (antibody, CAB005054). (C) High staining and strong intensity of HDAC3 in HCC (antibody, CAB005583). (D) Low expression of HDAC3 in normal liver tissue (antibody, CAB005583). (E) High staining and strong intensity of SHC1 in HCC (antibody, CAB016305). (F) Low expression of SHC1 in normal liver tissue (antibody, CAB016305). (G) Medium staining and average intensity of RAC1 in HCC (antibody, CAB035994). (H) Low expression of RAC1 in normal liver tissue (antibody, CAB035994). (I) High staining and strong intensity of IGF1R in HCC (antibody, CAB010268). (J) Medium staining of IGF1R in normal liver tissue (antibody, CAB010268). (K) Medium staining and average intensity of CBL in HCC (antibody, HPA027956). (L) Low expression of CBL expression in normal liver tissue (antibody, HPA027956). HCC, hepatocellular carcinoma; miR, microRNA; HDAC, histone deacetylate; SHC1, SHC-transforming protein 1; RAC1, Ras-related protein Rac1; IGF1R, insulin like growth factor 1 receptor; CBL, E3 ubiquitin-protein ligase CBL.](ol-18-06-6126-g10){#f9-ol-0-0-10962}

![Expression of potential target genes from the Gene Expression Omnibus database. Expression of HDAC2 in (A) Roessler\'s dataset and (B) Chen\'s dataset. Expression of HDAC3 in (C) Chen\'s dataset. Expression of RAC1 in (D) Roessler\'s dataset. Expression of SHC1 in (E) Roessler\'s dataset. HDAC, histone deacetylate; SHC1, SHC-transforming protein 1; RAC1, Ras-related protein Rac1.](ol-18-06-6126-g11){#f10-ol-0-0-10962}

![Association of hub gene expression and OS in patients with hepatocellular carcinoma using the Kaplan-Meier method based on The Cancer Genome Atlas cohort. (A) Association of HDAC2 (P=0.0007), (B) HDAC3 (P=0.0435), (C) SHC1 (P=0.0281) and (D) RAC1 (P=0.0022) expression and OS. OS, overall survival; HDAC, histone deacetylate; SHC1, SHC-transforming protein 1; RAC1, Ras-related protein Rac1.](ol-18-06-6126-g12){#f11-ol-0-0-10962}

###### 

Characteristics of the studies included in the meta-analysis.

  Author, year             Country       Series      Platform   HCC samples   Non-HCC samples   (Refs.)
  ------------------------ ------------- ----------- ---------- ------------- ----------------- ------------------------
  Li *et al*, 2008         China         GSE10694    GPL6542    78            88                ([@b89-ol-0-0-10962])
  Su *et al*, 2009         China         GSE12717    GPL7274    10            6                 ([@b90-ol-0-0-10962])
  Burchard *et al*, 2010   USA           GSE22058    GPL10457   96            96                ([@b91-ol-0-0-10962])
  Sato *et al*, 2011       Japan         GSE21362    GPL10312   73            73                ([@b92-ol-0-0-10962])
  Noh *et al*, 2013        South Korea   GSE39678    GPL15852   16            8                 ([@b93-ol-0-0-10962])
  Wang *et al*, 2012       USA           GSE31383    GPL10122   9             10                ([@b94-ol-0-0-10962])
  Morita *et al*, 2016     Japan         GSE41874    GPL7722    3             4                 ([@b95-ol-0-0-10962])
  Shih *et al*, 2012       Taiwan        GSE36915    GPL8179    68            21                ([@b96-ol-0-0-10962])
  Wojcicka *et al*, 2014   Poland        GSE63046    GPL11154   24            24                ([@b97-ol-0-0-10962])
  Shen *et al*, 2014       USA           GSE54751    GPL18262   10            10                ([@b98-ol-0-0-10962])
  Lou *et al*, 2019        Taiwan        GSE69580    GPL10850   5             5                 ([@b99-ol-0-0-10962])
  Murakami *et al*, 2015   Japan         GSE57555    GPL18044   5             16                ([@b100-ol-0-0-10962])
  Ghosh *et al*, 2016      India         GSE67882    GPL10850   4             8                 ([@b101-ol-0-0-10962])
  Peng *et al*, 2015       USA           GSE64632    GPL18116   3             3                 ([@b102-ol-0-0-10962])
  Zhang *et al*, 2017      China         GSE98269    GPL20712   3             3                 ([@b103-ol-0-0-10962])
  Shi *et al*, 2018        China         GSE115016   GPL21572   12            12                ([@b104-ol-0-0-10962])
  TCGA, 2018               N/A           N/A         N/A        372           50                --
  Chen *et al*, 2013       China         N/A         N/A        15            15                ([@b12-ol-0-0-10962])

HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; N/A, not available.

###### 

Association of miR-100-5p expression and clinicopathological parameters in HCC.

  Parameters    n     miR-100-5p expression (2^−ΔCq^), mean ± SD   t        P-value
  ------------- ----- -------------------------------------------- -------- ---------
  Sex                                                                       
    Male        253   12.2301±1.4228                               1.330    0.185
    Female      119   11.9950±1.6634                                        
  Age, years                                                                
    \<65        222   12.0354±1.5341                               −1.979   0.049
    ≥65         149   12.3490±1.4388                                        
  T                                                                         
    T1+T2       276   12.2602±1.4053                               2.313    0.022
    T3+T4       93    11.8000±1.7363                                        
  N                                                                         
    Yes         4     10.9563±2.2066                               1.575    0.116
    No          254   12.1331±1.4717                                        
  M                                                                         
    Yes         4     12.1561±1.1603                               −0.092   0.927
    No          269   12.0859±1.5263                                        
  Stage                                                                     
    I+II        258   12.2622±1.4063                               2.355    0.020
    III+IV      90    11.7777±1.7662                                        
  Grade                                                                     
    G1+G2       231   12.4402±1.4008                               4.964    \<0.001
    G3+G4       137   11.6580±1.5585                                        
  Child-Pugh                                                                
    A           220   12.2815±1.4836                               −0.548   0.584
    B+C         22    12.4645±1.6079                                        
  HBV/HCV                                                                   
    Yes         156   12.2373±1.4439                               −0.530   0.596
    No          197   12.1527±1.5251                                        
  Alcohol                                                                   
    Yes         117   12.2012±1.4718                               0.098    0.922
    No          236   12.1846±1.4994                                        
  NAFLD                                                                     
    Yes         19    12.9891±0.6046                               5.229    \<0.001
    No          334   12.1447±1.5110                                        
  AFP (ng/ml)                                                               
    \<400       216   12.3754±1.4072                               4.071    \<0.001
    ≥400        65    11.3984±1.7744                                        
  Cirrhosis                                                                 
    Yes         80    12.3822±1.3630                               −0.568   0.571
    No          135   12.2631±1.5524                                        

HBV, hepatitis B; HCV, hepatitis C; NAFLD, non-alcoholic fatty liver disease; AFP, α-fetoprotein.
